Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: A 1-year, multiccntcr, double-masked, placebo-controlled parallel study

Archives of Ophthalmology

Volumn 122, Issue 11, 2004, Pages 1667-1674

  Siatkowski, R Michael ^a   Cotter, Susan ^b   Miller, Joseph M ^c   Scher, Colin A ^d   Crockett, R Stephens ^e   Novack, Gary D ^f  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b S California College of Optomety   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

^e DATA Inc   (United States)

^f PHARMALOGIC DEVELOPMENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RESIDUE; PIRENZEPINE; PLACEBO;

ABDOMINAL PAIN; ACCIDENT; ACCOMMODATION; ANTICHOLINERGIC EFFECT; ARTICLE; ASTIGMATISM; CLINICAL TRIAL; COMMON COLD; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRY EYE; ERYTHEMA; EYE AXIS LENGTH; EYE BURN; EYE DISEASE; EYE INFECTION; EYE PAIN; EYE REFRACTION; EYELID; EYELID DISEASE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GEL; HEADACHE; HUMAN; HYPEREMIA; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYDRIASIS; MYOPIA; OCULAR PRURITUS; PAPULE; PHARYNGITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT;

CHILD; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; MUSCARINIC ANTAGONISTS; MYOPIA; OPHTHALMIC SOLUTIONS; PIRENZEPINE; REFRACTION, OCULAR; SAFETY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 8144228992     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.11.1667     Document Type: Article

References (30)

1. Sperduto RD, Seigel D, Roberts J, Rowland M. Prevalence of myopia in the United States. Arch Ophthalmol. 1983;101:405-407.
2. Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1994;35:4344-4347.
3. Framingham Offspring Eye Study Group. Familial aggregation and prevalence of myopia in the Framingham Offspring Eye Study. Arch Ophthalmol. 1996;114:326-332.
4. Negrel AD, Thylefors B. The global impact of eye injuries. Ophthalmic Epidemiol. 1998;5:143-169.
5. Shih Y-F, Chen C-H, Chou A-C, et al. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999;15:85-90.
6. Shih YF, Hsiao CK, Chen CJ. et al. An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression. Acta Ophthalmol Scand. 2001;79:233-236.
7. Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21:180-187.
8. McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci 1993;34:205-215.
9. Fischer AJ, Miethke P, Morgan IG, Stell WK. Cholinergic amacrine cells are not required for the progression and atropine-mediated suppression of form-deprivation myopia. Brain Res. 1998;794:48-60.
10. Schaeffel F, Troilo D, Wallman J, Howland HC. Developing eyes that lack accommodation grow to compensate for imposed defocus. Vis Neurosci. 1990;4:177-183.
11. Norton TT, Essinger JA, McBrien NA. Lid-suture myopia in tree shrews with retinal ganglion cell blockade. Vis Neurosci. 1994;11:143-153.
12. Stone RA, Lin T, Laties AM. Muscarinic antagonist effects on experimental chick myopia [letter] Exp Eye Res. 1991;52:755-758.
13. Carmine AA, Brogden RN. Pirenzepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985;30:85-126.
14. Dorje F, Wess J, Lambrecht G, et al. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991;256:727-733.
15. Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989;35:469-476.
16. Leech EM, Cottriall CL, McBrien NA. Pirenzepine prevents form deprivation myopia in a dose dependent manner. Ophthalmic Physiol Opt. 1995;15:351-356.
17. Cottriall CL, McBrien NA. The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. Invest Ophthalmol Vis Sci. 1996;37:1368-1379.
18. Tigges M, Iuvone PM, Fernandes A, et al. Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys. Optom Vis Sci. 1999;76:397-407.
19. Shedden AH, Sciberras D, Hutzelmann J, van Nispen C. Tolerability of pirenzepine ophthalmic solution in adult male volunteers [ARVO abstract] Invest Ophthalmol Vis Sci. 1998;39:5279.
20. Bartlett JD, Niemann K, Houde B, et al. Safety and tolerability of pirenzepine ophthalmic gel in pediatric myopic patients. J Ocul Pharmacol Ther. 2003;19:271-279.
21. Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91-96.
22. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials. 1984;5:348-361.
23. Osterlind G. An investigation into the presence of lymphatic tissue in the human conjunctiva, and its biologic and clinical importance. Acta Ophthalmol (Copenh). 1944;23:1-79.
24. Eye Disease Case-Control Study Group. Risk factors for idiopatnic rhegmatogenous retinal detachment. Am J Epidemiol. 1993;137:749-757.
25. Perkins ES. Morbidity from myopia. Sight Sav Rev. 1979;49:11-19.
26. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003;44:1492-1500.
27. Stone RA, Lin T, Laties AM, luvone PM. Retinal dopamine and form-deprivation myopia. Proc Natl Acad Sci U S A. 1989;86:704-706.
28. Iuvone PM, Tigges M, Stone RA, et al. Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia. Invest Ophthalmol Vis Sci. 1991;32:1674-1677.
29. Guo SS, Sivak JG, Callender MG, Diehl-Jones B. Retinal dopamine and lens-induced refractive errors in chicks. Curr Eye Res. 1995;14:385-389.
30. Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scierai chondrocytes. Invest Ophthalmol Vis Sci. 1998; 39:2217-2231.